Department of Internal Medicine and the Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Center for Tropical and Infectious Diseases (CENTRID), Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia.
Thromb Haemost. 2022 Dec;122(12):2001-2010. doi: 10.1055/s-0042-1757163. Epub 2022 Oct 11.
Coronavirus disease 2019 (COVID-19) is often associated with mild thrombocytopenia and increased platelet reactivity.
The aim of the current study was to investigate the adenosine triphosphate (ATP) release kinetics of platelets in hospitalized SARS-CoV-2-infected patients.
We studied time-dependent platelet activation in whole blood by monitoring the ATP release kinetics upon stimulation with a PAR1 receptor agonist in 41 hospitalized critically ill COVID-19 patients, 47 hospitalized noncritically ill COVID-19 patients, and 30 healthy controls.
Our study demonstrated that platelets of critically ill COVID-19 patients were hyper-responsive with a shorter platelet response time (PRT) and a reduced platelet granule release capacity (GRC), probably due to chronic activation. The median PRT of COVID-19 patients admitted to the critical care unit was 10 and 7 seconds shorter than the median PRT in healthy controls and noncritical COVID-19 patients, respectively. Both PRT and GRC were also associated with D-dimer (Spearman [ ] = -0.51, < 0.0001 and = -0.23, 0.05), C-reactive protein (CRP) ( = -0.59, < 0.0001 and = -0.41, < 0.01), and neutrophil-to-lymphocyte ratio (NLR) ( = -0.42, < 0.0001 and = -0.26, < 0.05). Moreover, an increased PRT and a reduced GRC were associated with an increased mortality (odds ratio [OR]: 18.8, 95% confidence interval [CI]: 6.5-62.8, 0.0001 and OR: 4.0; 95% CI: 1.6-10.4, 0.01). These relationships remained significant after adjustment for age, sex, D-dimer, CRP, and NLR.
Using an accessible agonist-induced platelet granule ATP release assay, we show that platelet hyper-responsiveness and reduced platelet GRC in COVID-19 patients were associated with critical illness and mortality.
新型冠状病毒病 2019(COVID-19)常伴有轻度血小板减少症和血小板反应性增高。
本研究旨在探讨住院 SARS-CoV-2 感染患者血小板三磷酸腺苷(ATP)释放动力学。
我们通过监测 PAR1 受体激动剂刺激后全血中血小板 ATP 释放动力学,研究了 41 例住院危重症 COVID-19 患者、47 例住院非危重症 COVID-19 患者和 30 例健康对照者的血小板随时间的激活情况。
本研究表明,危重症 COVID-19 患者的血小板反应过度,血小板反应时间(PRT)更短,血小板颗粒释放能力(GRC)降低,这可能是由于慢性激活所致。入住重症监护病房的 COVID-19 患者的中位 PRT 比健康对照组和非危重症 COVID-19 患者的中位 PRT 分别短 10 和 7 秒。PRT 和 GRC 也与 D-二聚体(Spearman [ ] = -0.51, < 0.0001 和 = -0.23, 0.05)、C 反应蛋白(CRP)( = -0.59, < 0.0001 和 = -0.41, < 0.01)和中性粒细胞与淋巴细胞比值(NLR)( = -0.42, < 0.0001 和 = -0.26, < 0.05)相关。此外,PRT 升高和 GRC 降低与死亡率增加相关(比值比 [OR]:18.8,95%置信区间 [CI]:6.5-62.8, < 0.0001 和 OR:4.0;95% CI:1.6-10.4, 0.01)。在调整年龄、性别、D-二聚体、CRP 和 NLR 后,这些关系仍然显著。
使用一种易于获得的激动剂诱导的血小板颗粒 ATP 释放测定法,我们发现 COVID-19 患者的血小板反应过度和血小板 GRC 降低与危重症和死亡率相关。